STOCK TITAN

Aim Immunotech - AIM STOCK NEWS

Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.

Overview of AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company engaged in the research and development of advanced therapeutics to address critical challenges in cancer therapy, immune-deficiency disorders, and viral diseases. With a robust focus on clinical research and strategic development, the company leverages cutting-edge biotechnology to transform the landscape of therapeutic solutions. Key industry terms such as immuno-pharma, therapeutics, and clinical trials are embedded in its research activities, underlining its commitment to modern, science-driven treatments.

Core Business Areas

AIM ImmunoTech concentrates on two major product categories. The first is an injectable formulation of naturally derived alpha interferon, designed to address specific sexually transmitted diseases, such as the treatment of certain genital warts. The second flagship therapeutic, Ampligen, is a macromolecular ribonucleic acid molecule deployed in clinical trials targeting conditions like chronic fatigue syndrome as well as multiple cancer types including renal cell carcinoma, malignant melanoma, and advanced recurrent ovarian cancer. The company’s interest in Ampligen also extends to exploring its potential as an adjuvant therapy in infectious diseases, as evidenced by its research in combination with interferon and other immune modulators.

Research, Development, and Collaborations

At the heart of AIM ImmunoTech's operations lies a rigorous commitment to clinical innovation. The company is actively involved in multi-phase clinical investigations for various conditions, including studies on refractory cancers and assessments of its drugs as vaccine adjuvants. Collaborations with esteemed institutions, such as research agreements with international partners including the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., further underscore its strategic approach to expanding the therapeutic applications of its products. These partnerships illustrate a balanced research model that addresses both immunotherapy and anti-viral research, exemplifying the company’s proficiency in navigating complex biomedical landscapes.

Operational Excellence and Strategic Positioning

AIM ImmunoTech has established itself within a competitive biopharmaceutical sector by consistently pursuing clinical research excellence and targeting unmet medical needs. Its therapeutic portfolio is designed to harness the body’s natural immune response while providing innovative clinical solutions across multiple health conditions. The company’s research efforts are supported by rigorous clinical trials and detailed investigations which focus on enhancing drug efficacy and safety. With its diversified pipeline, the company demonstrates a strategic approach to mitigating risks associated with clinical development and capitalizing on opportunities within the evolving landscape of cancer and viral treatment modalities.

Market Significance and Competitive Landscape

The company occupies a unique niche within the immuno-pharma market. Unlike larger, more diversified pharmaceutical companies, AIM ImmunoTech’s focused approach on specialized therapeutics positions it as a significant contributor to niche therapeutic areas that remain underexplored by mainstream industry players. Its collaborative research strategy and emphasis on innovative therapies such as Ampligen have helped bolster its standing within a highly competitive market. AIM’s approach combines the rigors of clinical research with strategic partnerships, ensuring that its products are developed with precision and scientific integrity.

Scientific Rigor and Clinical Expertise

Clinical investigations conducted by AIM ImmunoTech are characterized by meticulous study design and scientific scrutiny. The company has been involved in numerous phase 1, 2, and exploratory trials that seek to validate the efficacy of its compounds across various challenging conditions. By integrating detailed clinical protocols and a commitment to evidence-based research, AIM ImmunoTech showcases a depth of expertise and a nuanced understanding of the interrelationships between diverse medical conditions such as cancer, chronic fatigue syndrome, and viral infections.

Conclusion

Overall, AIM ImmunoTech Inc. stands as a model of focused innovation within the immuno-pharma sector. Its sustained commitment to advancing clinical research, developing groundbreaking therapeutics, and fostering strategic international collaborations provides a comprehensive insight into its business operations. For those seeking an in-depth understanding of a company dedicated to transforming therapeutic paradigms in oncology and virology, AIM ImmunoTech represents a case study in applied scientific expertise and clinical diligence.

Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has released a new CEO Corner segment on its website. In this segment, CEO Thomas Equels discusses the positive data from the Phase 1 clinical trial that investigated an Ampligen-containing chemokine modulation therapy used in combination with the chemotherapy drug paclitaxel. The trial focused on the treatment of early stage, triple-negative breast cancer. This update provides investors with insights into the company's progress in developing potential cancer treatments and its ongoing clinical research efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has announced new pre-clinical data on its drug Ampligen as part of a combination therapy for melanoma treatment. The study, published in the journal Vaccines, shows that combining dendritic cell-based vaccines with anti-PD-L1 checkpoint inhibitors and Ampligen-containing chemokine modulation helped slow tumor cell growth and improved survival in a mouse model.

Dr. David Strayer, AIM's Medical Officer, stated that this data further demonstrates Ampligen's therapeutic potential when used with dendritic-cell vaccines, anti-PD-L1 checkpoint inhibitors, or in combination with both. The company believes this supports their ongoing development of Ampligen as an anti-tumor therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech announced the release of a new CEO Corner segment on their website. CEO Thomas Equels provided updates on the Phase 1b/2 DURIPANC study for a combination therapy of Ampligen and AstraZeneca's Imfinzi targeting late-stage pancreatic cancer. Additionally, the company reported a stockholders' equity of $6.9 million as a result of recent financings. The full CEO Corner segment can be accessed on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
Rhea-AI Summary

AIM ImmunoTech will participate in the Virtual Investor Pitch Conference on June 17, 2024, at 1:00 PM ET. CEO Thomas K. Equels will deliver an elevator pitch outlining the company's upcoming milestones. Investors can submit questions live during the event, with responses provided within the time constraints. The live video webcast will be available on AIM ImmunoTech's website, with a replay accessible for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
conferences
-
Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) announced that CEO Thomas K. Equels will participate in the Virtual Investor Lunch Break Series on June 5, 2024, at 12:00 PM ET. During the event, Mr. Equels will give a corporate overview and discuss the company's business outlook. Attendees can submit questions live, which Mr. Equels will address. The live webcast will be available on the company’s website, and a replay will be accessible for 90 days two hours after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
-
Rhea-AI Summary

AIM ImmunoTech announced a $2 million registered direct offering with a single institutional investor. The deal includes the purchase of 5,640,958 shares of common stock at $0.363 per share and unregistered Class A and Class B warrants to buy an additional 5,640,958 shares each. The Class A warrants expire 18 months from issuance, while Class B warrants expire in five years. Maxim Group acts as the sole placement agent. The gross proceeds are around $2 million before fees and expenses. The offering is made under a shelf registration statement effective since February 4, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

AIM ImmunoTech announced that its CEO, Thomas K. Equels, will participate in two upcoming investor conferences. The first event, the Healthcare Company Showcase hosted by Alliance Global Partners, will take place on May 21, 2024, at 3:20 PM ET. The second event, LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar, is scheduled for May 22, 2024, at 3:40 PM ET. Both presentations will be webcast live and accessible via the Events page on AIM ImmunoTech's Investor section of their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences
-
Rhea-AI Summary

AIM ImmunoTech reported its Q1 2024 financial results, showing a net loss of $5.8 million, or $0.12 per share, compared to $3.7 million, or $0.08 per share, in Q1 2023. Cash reserves are at $10.9 million. The company highlighted progress in its Ampligen clinical programs, including positive interim data in ovarian cancer and the completion of cGMP manufacturing of 9,000 vials. AIM also announced that the first dose in a Phase 1b/2 study for late-stage pancreatic cancer was well-tolerated. Upcoming milestones include final data for Post-COVID Conditions in Q2 2024. AIM will host a conference call today, May 16, 2024, to discuss these results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
-
Rhea-AI Summary

AIM ImmunoTech Inc. will hold a conference call and webcast on May 16, 2024, to discuss Q1 2024 operational and financial results. The call will be led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer. Participants can join via phone or webcast on the aimimmuno.com website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
Rhea-AI Summary

AIM ImmunoTech Inc. has completed cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), a dsRNA product candidate for cancer, viral diseases, and immune disorders. CEO Thomas K. Equels emphasized the importance of this milestone for the company's development and commercial strategies, highlighting ongoing clinical trials for solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none

FAQ

What is the current stock price of Aim Immunotech (AIM)?

The current stock price of Aim Immunotech (AIM) is $0.0949 as of April 4, 2025.

What is the market cap of Aim Immunotech (AIM)?

The market cap of Aim Immunotech (AIM) is approximately 5.1M.

What is the core focus of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. is primarily focused on the research and development of novel therapeutics to treat various forms of cancer, immune-deficiency disorders, and viral diseases.

What are the main therapeutic products developed by AIM ImmunoTech?

The company develops products such as an injectable formulation of natural alpha interferon for certain STDs and Ampligen, a macromolecular RNA-based molecule investigated for cancer, chronic fatigue syndrome, and viral infections.

How does AIM ImmunoTech position itself within the biopharmaceutical industry?

The company positions itself by focusing on specialized therapeutic areas and leveraging robust clinical research and collaborations with renowned international partners to validate its compounds.

What is the significance of Ampligen in AIM ImmunoTech’s product portfolio?

Ampligen plays a key role as a versatile therapeutic candidate that is being evaluated for its efficacy in treating a range of conditions including various cancers, chronic fatigue syndrome, and its potential as a vaccine adjuvant.

How does the company approach clinical research and product development?

AIM ImmunoTech emphasizes rigorous clinical trial methodologies, strategic partnerships, and detailed research protocols to ensure that its therapeutic candidates meet high standards of safety and efficacy.

What distinguishes AIM ImmunoTech from other companies in the immuno-pharma sector?

Its focused approach on niche therapeutic areas, commitment to innovative clinical research, and strategic international collaborations allow AIM ImmunoTech to address unmet medical needs and differentiate itself within a competitive market.
Aim Immunotech

NYSE:AIM

AIM Rankings

AIM Stock Data

5.09M
67.24M
10.11%
12.54%
4.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
OCALA